

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

NCI-H322M

RRID:CVCL_1557

Type: Cell Line

Proper Citation

RRID:CVCL_1557

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1557

Proper Citation: RRID:CVCL_1557

Description: Cell line NCI-H322M is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Minimally invasive lung adenocarcinoma

Defining Citation: [PMID:2041050](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:22068913](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22628656](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31733513](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Caution: We are not certain that NCI-H322 and NCI-H322M are identical., Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H322M

Synonyms: NCI.H322M, H322M, H-322M, H-322m

Cross References: BTO:BTO_0004182, CLO:CLO_0037034, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:963, cancercellines:CVCL_1557, Cell_Model_Passport:SIDM00117, ChEMBL-Cells:ChEMBL3307710, ChEMBL-

Targets:CHEMBL614803, Cosmic:875851, Cosmic:905967, Cosmic:974293, Cosmic:1092620, Cosmic:1175865, Cosmic:1305348, Cosmic:1312333, Cosmic:1995574, Cosmic:1998462, Cosmic:2772153, Cosmic-CLP:905967, DepMap:ACH-002172, EGA:EGAS00001000978, GDSC:905967, GEO:GSM2131, GEO:GSM50215, GEO:GSM50278, GEO:GSM434296, GEO:GSM743454, GEO:GSM750802, GEO:GSM799342, GEO:GSM799405, GEO:GSM1153413, GEO:GSM1181269, GEO:GSM1181316, GEO:GSM1374742, GEO:GSM1670239, GEO:GSM2124675, IARC_TP53:21407, IGRhCellID:H322M_03GEO, LINCS_LDP:LCL-1674, NCI-DTP:NCI-H322M, PharmacDB:NCIH322M_1106_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1557, PubChem_Cell_line:CVCL_1557, SKY/M-FISH/CGH:2797, Wikidata:Q54908034

ID: CVCL_1557

Hierarchy: cvcl_1556

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181245+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H322M.

No alerts have been found for NCI-H322M.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Bagnyukova T, et al. (2024) Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. Cancer research communications, 4(5), 1227.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Dexheimer TS, et al. (2023) Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. Cancer research communications, 3(8), 1648.

Pal AS, et al. (2022) Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET. Cancer research, 82(8), 1534.